Aurinia Pharmaceuticals (AUPH)
NASDAQ:AUPH
AUPHAurinia Pharmaceuticals
$13.38
-$0.1 (-0.74%)

Aurinia Pharmaceuticals Stock Analysis & Ratings

Aurinia Pharmaceuticals Stock Analysis Overview

Smart Score
6
Neutral
1
2
3
4
5
6
7
8
9
10
Learn more about TipRanks Smart Score
The Aurinia Pharmaceuticals stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.

Stock Chart

AUPH

AUPH Stock Stats

Previous Close$13.48
Open$13.55
Bid13.38 x 200
Ask13.4 x 1800
Today’s Range$13.29 - $13.61
52-Week Range$9.72 - $20.50
Volume259.34K
Average Volume3.51M
Market Cap$1.71B
Beta0.52
P/E Ratio-12.2
EPS-1.40
Earnings DateAug 05, 2021

Company Description

Aurinia Pharmaceuticals

Aurinia Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company, which engages in the development of a therapeutic drug to treat autoimmune diseases particularly lupus nephritis. The company was founded by Robert Foster, Richard Glickman and Michael Martin on June 16, 1993 and is headquartered in Victoria, Canada.
Sector
Healthcare
Industry
Biotechnology
CEO
Peter S. Greenleaf
Employees
294
Address
4464 Markham Street, Victoria, BC, V8Z 7X8, CA

Financials


P/E Ratio Range

The price to earnings ratio. This is used by investors to assess a stock’s market price relative to its earnings.

Aurinia Pharmaceuticals News


AUPH FAQ

What was Aurinia Pharmaceuticals’s price range in the past 12 months?
Aurinia Pharmaceuticals lowest stock price was $9.72 and its highest was $20.50 in the past 12 months.
    What is Aurinia Pharmaceuticals’s market cap?
    Aurinia Pharmaceuticals’s market cap is $1.71B.
      What is Aurinia Pharmaceuticals’s price target?
      The average price target for Aurinia Pharmaceuticals is $27.40. This is based on 5 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
      The highest analyst price target is $35.00 ,the lowest forecast is $23.00. The average price target represents 104.78% Increase from the current price of $13.38.
        What do analysts say about Aurinia Pharmaceuticals?
        Aurinia Pharmaceuticals’s analyst rating consensus is a ‘Strong Buy. This is based on the ratings of 5 Wall Streets Analysts.
          When is Aurinia Pharmaceuticals’s upcoming earnings report date?
          Aurinia Pharmaceuticals’s upcoming earnings report date is Aug 05, 2021 which is tomorrow.
            How were Aurinia Pharmaceuticals’s earnings last quarter?
            Aurinia Pharmaceuticals released its earnings results on May 06, 2021. The company reported -$0.401 earnings per share for the quarter, missing the consensus estimate of -$0.371 by -$0.03.
              Is Aurinia Pharmaceuticals overvalued?
              According to Wall Street analysts Aurinia Pharmaceuticals’s price is currently Undervalued.
                Does Aurinia Pharmaceuticals pay dividends?
                Aurinia Pharmaceuticals does not currently pay dividends.
                What is Aurinia Pharmaceuticals’s EPS estimate?
                Aurinia Pharmaceuticals’s EPS estimate for its next earnings report is not yet available.
                How many shares outstanding does Aurinia Pharmaceuticals have?
                Aurinia Pharmaceuticals has 128,230,000 shares outstanding.
                  What happened to Aurinia Pharmaceuticals’s price movement after its last earnings report?
                  Aurinia Pharmaceuticals reported an EPS of -$0.401 in its last earnings report, missing expectations of -$0.371. Following the earnings report the stock price went down -17.359%.
                    Which hedge fund is a major shareholder of Aurinia Pharmaceuticals?
                    Among the largest hedge funds holding Aurinia Pharmaceuticals’s share is HealthCor Management, L.P.. It holds Aurinia Pharmaceuticals’s shares valued at 12M.

                      What's Included in PREMIUM?
                      Make informed decisions based on Top Analysts' activity
                      Know what industry insiders are buying
                      Get actionable alerts from top Wall Street Analysts
                      Find out before anyone else which stock is going to shoot up
                      Get powerful stock screeners & detailed portfolio analysis